Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Abbott profit, sales beat estimates on vigorous COVID test demand

Stock MarketsJan 26, 2022 11:26AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, 2021. REUTERS/Brendan McDermid/File Photo

By Leroy Leo and Carl O'Donnell

(Reuters) -Abbott Laboratories on Wednesday beat quarterly profit and sales estimates, aided by robust sales of COVID-19 test kits and strong demand for its diagnostics products, but forecast lower-than-expected COVID-19 testing sales in 2022 due to uncertainties around the future of the pandemic.

The U.S. medical device maker traded down as much as 2.7% Wednesday morning following its earnings release.

Abbott said it expects $2.5 billion in sales of COVID-19 test kits in the early part of this year. The company will update its test kit estimates on a quarterly basis.

"COVID testing is going to still be around," said Chief Executive Officer Robert Ford during an investor call. "The question is just how does it evolve over the next nine to 12 months."

Test makers have grappled with choppy demand in the past few quarters as COVID infections have surged and plateaued in the United States, making it difficult to predict whether demand will hold up for the long term.

Analysts were expecting Abbott to be conservative with its COVID test forecast due to uncertainties around the pandemic.

The U.S. government in September announced plans to acquire billions of dollars worth of COVID rapid tests from manufacturers including Abbott in a bid to boost supplies around the country. [L1N2R228S]

Abbott said it would be closely looking at acquisition opportunities in medical devices and diagnostics tools this year.

The Illinois-based company posted $2.3 billion in COVID test sales for the fourth quarter, including $2.1 billion in rapid tests. The overall COVID test sales were marginally lower than the $2.4 billion it reported a year ago.

The company had previously expected COVID test-related sales to be between $1.0 billion and $1.4 billion in the quarter.

Abbott forecast adjusted earnings from continuing operations of at least $4.70 per share for the year, below analysts' estimates of $4.78.

Fourth-quarter sales in Abbott's diagnostics business were $4.47 billion, beating analysts' estimates of $3.46 billion.

On an adjusted basis, Abbott earned $1.32 per share, beating estimates of $1.21, according to Refinitiv IBES data.

Total sales were $11.5 billion, higher than the $10.7 billion estimated by analysts.

Abbott profit, sales beat estimates on vigorous COVID test demand
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email